Mangoceuticals, Inc. (MGRX)

Mangoceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-20.64	-8.71	-9.21	-2
Depreciation & Amortization	1.72	0.73	0.02	0
Stock-Based Compensation	11.89	2.35	2.16	0.77
Other Adjustments	0.21	0.1	0.05	-0.15
Changes in Inventories	-	-	-0.02	-
Changes in Accounts Payable	0.06	0.63	0.11	0.03
Changes in Other Operating Activities	0.91	0.03	-0.1	-0.01
Operating Cash Flow	-5.85	-4.86	-7	-1.35
Capital Expenditures	-	-	-0	-0.04
Sale of Property, Plant & Equipment	-	0.07	-	-
Investing Cash Flow	-	0.07	-0	-0.04
Long-Term Debt Issued	0.68	0.15	-0.08	0.08
Long-Term Debt Repaid	-0.21	-	-0.09	-0.03
Net Long-Term Debt Issued (Repaid)	0.47	0.15	-0.17	0.05
Issuance of Common Stock	5.55	1.33	7.22	2
Net Common Stock Issued (Repurchased)	5.55	1.33	7.22	2
Issuance of Preferred Stock	0.1	2.65	-	-
Net Preferred Stock Issued (Repurchased)	0.1	2.65	-	-
Other Financing Activities	1.15	-	-	-
Financing Cash Flow	7.27	4.13	7.06	2.05
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.01	-0.01	-	-
Net Cash Flow	1.42	-0.67	0.06	0.66
Free Cash Flow	-5.85	-4.86	-7	-1.39
FCF Margin	-1282.89%	-789.74%	-957.07%	-15545.60%
Free Cash Flow Per Share	-0.58	-2.46	-6.52	-1.93
Levered Free Cash Flow	-17.49	-7.16	-9.37	-1.97
Unlevered Free Cash Flow	-16.47	-7.3	-9.21	-2.01

Updated Apr 1, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q